Research Center for Experimental Orthopaedics, Heidelberg University Hospital, Schlierbacher Landstr. 200a, 69118 Heidelberg, Germany.
Center of Orthopaedic and Trauma Surgery, Heidelberg University Hospital, Schlierbacher Landstr. 200a, 69118 Heidelberg, Germany.
Int J Mol Sci. 2019 Sep 2;20(17):4295. doi: 10.3390/ijms20174295.
Current therapies involving chondrocytes or mesenchymal stromal cells (MSCs) remain inefficient in restoring cartilage properties upon injury. The induced pluripotent stem-cell (iPSC)-derived mesenchymal progenitor cells (iMPCs) have been put forward as a promising alternative cell source due to their high proliferation and differentiation potential. However, the observed cell loss during in vitro chondrogenesis is currently a bottleneck in establishing articular chondrocyte generation from iPSCs. In a search for candidate mechanisms underlying the low iPSC-derived cartilage tissue yield, global transcriptomes were compared between iMPCs and MSCs and the cell properties were analyzed via a condensation assay. The iMPCs had a more juvenile mesenchymal gene signature than MSCs with less myofibroblast-like characteristics, including significantly lower ECM- and integrin-ligand-related as well as lower α-smooth-muscle-actin expression. This correlated with less substrate and more cell-cell adhesion, impaired aggregate formation and consequently inferior cohesive tissue properties of the iMPC-pellets. Along lower expression of pro-survival ECM molecules, like decorin, collagen VI, lumican and laminin, the iMPC populations had significantly less active ERK1/2 compared to MSCs. Overall, this study proposes that this ECM and integrin-ligand shortage, together with insufficient pro-survival ERK1/2-activity, explains the loss of a non-aggregating iMPC sub-fraction during pellet formation and reduced survival of cells in early pellets. Enhancing ECM production and related signaling in iMPCs may be a promising new means to enrich the instructive microenvironment with pro-survival cues allowing to improve the final cartilage tissue yield from iPSCs.
目前,涉及软骨细胞或间充质基质细胞(MSCs)的治疗方法在受伤后恢复软骨特性方面仍然效率低下。诱导多能干细胞(iPSC)衍生的间充质祖细胞(iMPC)因其高增殖和分化潜力而被提出作为一种有前途的替代细胞来源。然而,在体外软骨生成过程中观察到的细胞丢失目前是从 iPSC 建立关节软骨细胞生成的一个瓶颈。在寻找导致 iPSC 来源的软骨组织产量低的候选机制的过程中,比较了 iMPC 和 MSC 之间的全基因组转录组,并通过凝聚测定分析了细胞特性。iMPC 比 MSC 具有更年轻的间充质基因特征,具有更少的成肌纤维细胞样特征,包括显著更低的细胞外基质(ECM)和整合素配体相关特征,以及更低的α-平滑肌肌动蛋白表达。这与更少的基质和更多的细胞-细胞粘附、聚集形成受损以及随后 iMPC 微球较差的粘聚组织特性相关。随着促生存 ECM 分子,如饰胶蛋白聚糖、VI 型胶原、赖氨聚糖和层粘连蛋白的表达降低,iMPC 群体中 ERK1/2 的活性明显低于 MSC。总的来说,这项研究表明,这种 ECM 和整合素配体的缺乏,加上不足的促生存 ERK1/2 活性,解释了在微球形成过程中无聚集的 iMPC 亚群的丢失以及早期微球中细胞的存活率降低。增强 iMPC 中的 ECM 产生和相关信号转导可能是一种有前途的新方法,可以用促生存信号来丰富有指导意义的微环境,从而提高 iPSC 来源的最终软骨组织产量。